CD22 Antibody (HD39): sc-73363
- CD22 Antibody (HD39) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against Hairy Cell leukemia cells of human origin
- recommended for detection of normal and neoplastic B lymphocytes of human origin by IP, IF and FCM
- available conjugated to FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for CD22 Antibody (HD39). This reagent is now offered in a bundle with CD22 Antibody (HD39) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD22 Antibody (HD39) is a mouse monoclonal IgG1 antibody that detects CD22 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD22 is a critical regulator of B cell signaling and plays a vital role in the immune response by modulating B cell activation and proliferation. This integral membrane glycoprotein is primarily located on the surface of B lymphocytes, where CD22 functions as a cell adhesion molecule, facilitating interactions between B cells and other immune cells. CD22 expression on mature B cells is essential for maintaining immune tolerance and preventing autoimmunity, as CD22 helps to regulate the strength and duration of B cell receptor signaling. Additionally, CD22 undergoes alternative splicing, resulting in two isoforms, CD22α and CD22β, with CD22β being the predominant form. CD22′s ability to form heterodimers with its isoforms enhances functional diversity, allowing for fine-tuned regulation of B cell responses. Anti-CD22 antibody (HD39) is an invaluable tool for researchers studying B cell biology and related pathologies, including acute lymphocytic leukemia, where cytoplasmic CD22 serves as a significant marker.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD22 Antibody (HD39) References:
- CD22 regulates adaptive and innate immune responses of B cells. | Kawasaki, N., et al. 2011. J Innate Immun. 3: 411-9. PMID: 21178327
- Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model. | Wöhner, M., et al. 2012. Eur J Immunol. 42: 3009-18. PMID: 22965838
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. | Haso, W., et al. 2013. Blood. 121: 1165-74. PMID: 23243285
- CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. | Müller, J., et al. 2013. Proc Natl Acad Sci U S A. 110: 12402-7. PMID: 23836650
- CD22 is required for formation of memory B cell precursors within germinal centers. | Chappell, CP., et al. 2017. PLoS One. 12: e0174661. PMID: 28346517
- Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy. | Brandl, C., et al. 2020. Eur J Immunol. 50: 1834-1837. PMID: 32592176
- Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. | Liu, J., et al. 2022. MedComm (2020). 3: e140. PMID: 35665369
- High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy. | Abbaszade Dibavar, M., et al. 2024. In Vitro Cell Dev Biol Anim. 60: 321-332. PMID: 38589736
- Deciphering the importance of culture pH on CD22 CAR T-cells characteristics. | Prochazkova, M., et al. 2024. J Transl Med. 22: 384. PMID: 38659083
- Neu5Gc-mediated high-affinity interaction is dispensable for CD22 cis-ligands to regulate B cell signaling. | Akatsu, C., et al. 2024. J Biol Chem. 300: 107630. PMID: 39098526
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD22 Antibody (HD39) | sc-73363 | 200 µg/ml | $316.00 | |||
CD22 Antibody (HD39): m-IgG Fc BP-HRP Bundle | sc-539477 | 200 µg Ab; 10 µg BP | $354.00 | |||
CD22 Antibody (HD39) FITC | sc-73363 FITC | 200 µg/ml | $330.00 |